Follow RSS for latest reports on this topicGazyva (Obinutuzumab) - Market Research and Reports

GAZYVATM (obinutuzumab), in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).

Created at Glycart Biotechnology, Gazyva (obinutuzumab), a type II bioengineered anti-CD20 humanized IgG1 monoclonal, has been developed by Biogen Idec and Roche subsidiaries Genentech and Chugai Pharmaceutical. As with Rituxan® (rituximab), Zevalin® (ibritumomab tiuxetan) and Bexxar® (tositumomab), Gazyva binds to CD20, an activated-glycosylated phosphoprotein target expressed on the surface of all B-cells, causing cell death by apoptosis. It is indicated for use, in combination with chlorambucil, for the treatment of previously untreated CLL.

For full details open - 

Adapted from - Thomson Reuters Cortellis Competitive Intelligence

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...

or can supply a pro-forma invoice if required.

Related Reports:

We found 3 reports that matched your search.

Refine your search, and find more matches, using the form above.

Additional Searches

You may also like to search separately for: Gazyva (Obinutuzumab)

We Stock...